Press Releases Compugen Ltd.

Equities

CGEN

IL0010852080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.92 ^USD	+1.05%		+1.05%	-3.03%

Mar. 08	Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating	MT
Mar. 05	Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	Apr. 26	AQ
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	Apr. 25	PU
Compugen to Participate in Two Upcoming Investor Conferences	Apr. 03	PR
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	Mar. 11	PU
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	Mar. 11	PR
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	Mar. 07	AQ
Compugen : To Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	Mar. 06	PU
Compugen: Q4 Earnings Snapshot	Mar. 05	AQ
Compugen : Form 6-K- Fourth quarter and full year 2023 results	Mar. 05	PU
Compugen Reports Fourth Quarter and Full Year 2023 Results	Mar. 05	PR
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024	Feb. 26	PR
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024	Feb. 20	PR
Compugen names new chief medical officer	Feb. 16	AQ
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer	Feb. 15	PR
Compugen : 6K-License Agreement with Gilead and entitlement to receive a milestone payment of $10 million from AstraZeneca	Dec. 19	PU
Compugen: Q3 Earnings Snapshot	Nov. 07	AQ
Compugen Reports Third Quarter 2023 Results	Nov. 07	PR
Compugen's COM701 Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy	Nov. 07	AQ
Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023	23-09-27	PR
Compugen : Results of the Annual General Meeting of Shareholders held on September 20, 2023	23-09-21	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Compugen Ltd.

Equities

CGEN

IL0010852080

Press Releases

Filters